Patients who choose to continue to use the drug must review statements describing the cardiovascular safety concerns associated with Avandia and acknowledge they understand the risks. Their doctors must also attest to and document their patients’ eligibility.

The new rule applies to all drugs containing rosiglitazone, including Avandia , Avandamet (rosiglitazone and metformin) and Avandaryl (rosiglitazone and glimeperide).  GlaxoSmithKline, the maker of Avandia, says it will inform pharmacists and doctors about the new program over the next two months. Patients are advised to discuss their diabetes treatment options with their doctors.

More than 23 million Americans are believed to have type 2 diabetes, and nearly 500,000 Americans filled prescriptions for rosiglitazone in the first 10 months of 2010. At that point, prescriptions dropped considerably as news of the restrictions due to health risk were announced.

SOURCE: Avandia Recall › FDA to remove Avandia from retail pharmacies

A black box warning, or boxed warning, is the strongest warning the FDA can issue and is given to prescription drugs that may cause serious or life threatening health consequences. The boxed warning section describes the risk for congestive heart failure and myocardial infraction, or heart attack, as statistically significant based on clinical trials.

Also added to the warnings and precautions section of the safety information for rosiglitazone are warnings for cardiac failure, adverse cardiovascular events, and fractures. The adverse reactions section was also updated to include a possible increased risk for heart attack when Avandia is used in combination with insulin.

Last fall, the FDA voted to put tight restrictions on Avandia and other drugs in its class based on data from clinical trials that showed use of the drug put patients at risk for cardiovascular events such as heart attacks and strokes. The FDA also ordered makers of the drug to update the product’s safety label to include the warnings. Since the FDA’s ruling, in order for Americans to continue to receive the drug, their doctors must attest to and document their patients’ eligibility. Patients will also have to review statements describing the cardiovascular safety concerns associated with Avandia and acknowledge they understand the risks.

SOURCE: Avandia Recall › FDA approves new warnings on Avandia packaging

GSK was facing about 2,000 lawsuits alleging it covered up Avandia’s heart attack and stroke risks. The company previously agreed to pay about $460 million to resolve allegations it didn’t properly warn doctors and consumers about the medicine’s risk. That news brought more lawsuits against the GSK, and more settlements to the forefront.

The drug was pulled from the European market and severely restricted in the United States last September, after studies linked Avandia to an increased risk for cardiovascular events. This week, the Food and Drug Administration (FDA) approved label changes for Avandia and outlined the standards that patients must meet before they can take the drug.

Those guidelines state that the drug should only be used in patients already being treated with rosiglitazone, in patients whose blood sugar cannot be controlled with other anti-diabetic medications, and who, after consulting with their health care professional, do not wish to use pioglitazone-containing medications, another type of diabetes drug that includes the brands Actos, Actoplus Met, Actoplus Met XR, or Duetact.

Avandia is a single-ingredient product and is also sold as a combination product under the brand name Avandament (with metformin) and the brand name Avandaryl (with glimepride).

Studies suggest as many as 100,000 heart attacks may have been caused by the drug.

SOURCE: Avandia Recall › GSK pays out more money to settle lawsuits against deadly diabetes drug

The lixisenatide study sought to establish the efficacy and safety of using both lixisenatide and Lantus together. The clinical trials involving 311 patients in Asia with Type 2 diabetes showed those who had a difficult time keeping their blood sugar levels within safe limits with basal insulin alone, were helped by the addition of a daily lixisenatide injection. At least 60 percent of the patients took Lantus as their basal insulin.

Lixisenatide belongs to a class of drugs that work by imitating a hormone called GLP-1 to stimulate the pancreas to produce more insulin after meals. By the time the drug is expected to be approved, its main purpose will be in combination with Lantus.

Lixisenatide could offer more options to Type 2 diabetics, who last month were informed that prescriptions of the diabetes drug Avandia would be severely restricted after a review by the Food and Drug Administration (FDA) found the drug to increase the risk of cardiovascular events. Clinical trials showed lixisenatide to be generally well tolerated with no significant adverse events.

SOURCE: Avandia Recall › Experimental diabetes drug performs well in clinical trials

In order for Americans to continue to receive the drug, their doctors must attest to and document their patients’ eligibility. Patients will also have to review statements describing the cardiovascular safety concerns associated with Avandia and acknowledge they understand the risks. The FDA says it anticipates the tight restrictions will likely have a devastating impact on GlaxoSmithKline’s (GSK) Avandia, the sales of which topped $2 billion last year, down from $3.2 billion in 2006.

Avandia, known by the generic rosiglitazone, is in a class of drugs known as thiazolidinediones, or TZDs. It is intended to be used in conjunction with diet and exercise to improve blood sugar control in patients with Type 2 diabetes mellitus. Rosiglitazone is also available in combination with other diabetes medications, such as metformin under the brand name Avandament or glimepiride under the name Avandaryl.

Despite studies that suggest as many as 100,000 heart attacks may have been caused by Avandia, GSK has long insisted that its billion-dollar drug is safe, going so far as to hold its own study comparing Avandia with a similar medication, Actos. The FDA has ordered GSK to end the study.

The FDA also ordered GSK to convene an independent group of scientists to review key aspects of the company’s clinical trial known as RECORD, which studied the cardiovascular safety of Avandia compared to standard diabetes drugs. During a review of the data, the FDA questioned GSK’s potential bias in the identification of cardiovascular events.

The FDA is continuing to review complaints on the medication. Any side effects with Avandia, or any other medication, should be reported to the FDA Medwatch Adverse Event Reporting Program at www.FDA.gov/Medwatch.

Sources:
New York Times
FDA

SOURCE: Avandia Recall › FDA puts tight restrictions on Avandia due to heart attack, stroke risk

You can’t call it a vote of confidence. If anything, the approval will alert physicians to concerns that the drug puts people at greater risk of heart attacks and strokes, according to some studies. This will likely result in fewer prescriptions written for the Type 2 diabetes drug, which brought in $1 billion in sales last year with more than 2 million prescriptions filled.

The American Diabetes Association voted to unanimously advise that GlaxoSmithKline’s blockbuster drug not be used, and a majority of the FDA panel – 21 out of 33 members – say they believe Avandia puts users at greater risk of cardiovascular problems. But only 12 of the 33 members actually voted to keep the drug out of the market. Ten out of 33 voted to keep it available but only if its safety label included a strong warning statement.

Adding to GSK’s woes is a BBC current affairs report that aired Monday and focused on the safety of Avandia. Now, only European regulators can decide the future of Avandia in the U.K.

Source: Market Watch

SOURCE: Avandia Recall › U.K. advisory panel votes to remove diabetes drug Avandia from market

But don’t expect physicians to write as many prescriptions for the Type 2 diabetes drug as they have in the past. Avandia brought in $1 billion in sales last year with more than 2 million prescriptions filled. But studies showing heart attacks, strokes and cardiovascular-related deaths in people who used Avandia have prompted national experts in a Consensus Statement of the American Diabetes Association to unanimously advise that GlaxoSmithKline’s blockbuster medication not be used.

While Avandia will still be available, the FDA vote showed a strong majority – 21 out of 33 members – believe Avandia increases heart risk. Twelve out of 33 members voted to take it off the market, and 10 out of 33 voted to leave it on with strong restrictions.

And while the FDA advisory panel heard damning evidence on the safety of Avandia, it was reported that GSK had agreed to settle some 10,000 of the 13,000 lawsuits filed against it alleging that Avandia caused heart attacks or strokes.

What diabetics should glean from the vote is that they need to be aware that there is a dark cloud of suspicion hanging over the safety of Avandia, which should be enough evidence for them to consider the many safer alternatives on the market.

SOURCE: Avandia Recall › Dark cloud hangs over Avandia despite FDA vote to keep it on market

Avandia was approved by the Food and Drug Administration (FDA) in 1999 to treat Type 2 diabetes, the fastest growing form of diabetes. GSK launched a multimillion-dollar ad campaign to introduce the drug to the market, which brought in $1 billion in sales last year alone with more than 2 million prescriptions filled.

A 2007 study found that Avandia could increase the risk of heart attack by as much as 43 percent, and more recent studies suggest that Avandia may be responsible for thousands of cardiovascular events such as heart attacks, strokes and other heart problems. In 2007, an FDA panel reviewed the data but voted not to pull the drug off the market.

However, concerns over a new study on the drug has led the FDA to conduct a second review the safety of Avandia. The agency is also questioning whether GSK tried to cover up the risks associated with the drug.

The panel is expected to vote soon on whether to remove the popular diabetes drug from the market.

SOURCE: Avandia Recall › GSK to pay $460 million to settle Avandia lawsuits

Avandia, also known by the generic name rosiglitazone, faced the same panel in 2007, which voted 22-1 to keep the drug on the market despite a separate vote of 20-3 that there probably was a link to heart problems. Since then, several publications have come out both in support of and against the safety of Avandia. One major topic of this second go-round with the panel includes an analysis of the RECORD study, which the Food and Drug Administration’s Dr. Thomas Marciniak of the division of cardiovascular and renal products wrote, “was inadequately designed and conducted to provide any reassurance about the (cardiovascular) safety of rosiglitazone.”

The 5 ½-year RECORD study involved nearly 5,000 diabetes patients and showed that the drug was not related to an increase in cardiovascular events other than congestive heart failure, which is a documented side effect of drugs used to treat diabetes.

Avandia is a blockbuster medication approved in 1999 to treat Type 2 diabetes, the most common form of the disease. More than a million people in the U.S. have taken the drug. Studies have concluded that Avandia raised the risk of heart attacks in people who used the drug by as much as 43 percent compared to people taking no diabetes medication or other diabetes drugs. Studies have also indicated that Avandia might increase the risk of heart-related deaths.

However, GSK backs the RECORD study, which the FDA argues is “inappropriate and biased.” The panel is expected to vote soon whether to pull the popular diabetes drug off the market.

SOURCE: Avandia Recall › FDA panel to decide fate of diabetes drug Avandia

According to the FDA’s announcement, the “FDA previously communicated to the public about the possible association between rosiglitazone and increased cardiovascular risk in a 2007 safety alert. The agency also sought advice from external experts at the July 30, 2007, joint meeting of the FDA Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees. The RECORD study data represent the only new information from a completed randomized, controlled clinical trial of rosiglitazone received by FDA since the 2007 announcements.”

The RECORD study, which stands for Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes, was designed to evaluate the cardiovascular safety of rosiglitazone. This practice is consistent with the FDA’s December 2008 Guidance for Industry that recommends that manufacturers of new treatments for diabetes carefully design their clinical trials to include an evaluation of cardiovascular safety.

Once the FDA has completed its review of rosiglitazone, the agency will present its findings at a joint public meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees in July 2010.

Rosiglitazone, a treatment for Type 2 diabetes, is sold as a single-ingredient product under the brand name Avandia, and is available in combination with other diabetes medications, such as metformin, under the brand name Avandament, or glimepride, under the brand name Avandaryl. The FDA advises that patients who are currently taking any form of rosiglitazone should not stop taking their medication without first talking to their healthcare professional. Any side effects with this or any other medication should be reported to the FDA MedWatch Adverse Event Reporting program at www.fda.gov/medwatch.

SOURCE: Avandia Recall › FDA announces it will review studies linking Avandia to heart attacks

Avandia was approved by the FDA for the treatment of Type 2 diabetes in 1999, and grew to become a $3 billion a year industry for GSK. In 2007, a study was published in the New England Journal of Medicine that linked Advandia to a 43 percent increased risk of heart disease. The senators contend that the London-based GSK got its hands on a copy of the report before it was published and the drug company quickly initiated a public relations push to counter any questions about Avandia’s link to increased heart risk. The drug company also urged the medical researchers who identified the risk of heart and liver problems in patients taking Avandia to stop publishing their findings.

The effort kept the drug on the market, but GSK took a near-$2 billion hit in sales in 2009. A company spokeswoman said in a statement, “the scientific evidence simply does not establish that Avandia increases ischemic cardiovascular risk or causes myocardial ischemic events … Based on the scientific evidence and a recommendation by an independent advisory committee of experts convened by the FDA, the agency has ruled that Avandia remain available to patients for the treatment of Type 2 diabetes.”

Senators Baucus and Crassley disagree. “It can be argued that GSK had a duty to warn patients and the FDA of the Company’s concerns,” wrote Baucus and Grassley in the Senate committee report. “Instead, GlaxoSmithKline executives attempted to intimidate independent physicians, focused on strategies to minimize or misrepresent findings that Avandia may increase cardiovascular risk, and sought ways to downplay findings that a competing drug might reduce cardiovascular risk.”

Sources:
Business Week
New York Times

SOURCE: Avandia Recall › Senators ask why dangerous Avandia was not pulled from market